Latent Sensitization in a Mouse Model of Ocular Neuropathic Pain
Overview
Ophthalmology
Authors
Affiliations
Purpose: Chronic ocular pain is poorly understood and difficult to manage. We developed a murine model of corneal surface injury (CSI)-induced chronic ocular neuropathic pain. The study focuses on changes in corneal nerve morphology and associated short- and long-term pain-like behavior after CSI.
Methods: CSI was induced in mice by local application of an alkali solution (0.75 N NaOH). Corneal nerve architecture, morphology, density, and length were studied. Eye-wiping was evaluated before and after CSI in response to hypertonic saline (2 M NaCl). Naltrexone (NTX) or Naloxone-methiodide (NLX-me), opioid receptor antagonists, were given subcutaneously (s.c., 3 mg/kg) or topically (eye drop, 100 μM), and then an eye-wiping test was performed.
Results: CSI caused partial corneal deinnervation followed by gradual reinnervation. Regenerated nerves displayed increased tortuosity, beading, and branching. CSI enhanced hypertonic saline-induced eye-wiping behavior compared to baseline or sham-injury ( < 0.01). This hypersensitivity peaked at 10 days and subsided 14 days after CSI. Administration of NTX, or NLX-me, a selective peripheral opioid antagonist, reinstated eye-wiping behavior in the injury group, but not in the sham groups ( < 0.05).
Conclusions: This study introduces a model of chronic ocular pain and corneal neuropathy following CSI. CSI induces central and peripheral opioid receptor-dependent latent sensitization (LS) that is unmasked by systemic or topical administration of opioid antagonists.
Translational Relevance: This model of chronic ocular pain establishes LS as a new inhibitory mechanism in the oculotrigeminal system and may be used for potential diagnostic and therapeutic interventions for ocular neuropathy.
Diagnostic and evaluative efficiency of Ga-FAPI-04 in skeletal muscle injury.
Wang Y, Li L, Wang H, Cheng J, Du C, Xu L EJNMMI Res. 2024; 14(1):88.
PMID: 39356393 PMC: 11447190. DOI: 10.1186/s13550-024-01147-w.
Chemical toxic exposures and chronic ocular pain.
Graca M, Sarantopoulos K, Horn D Front Toxicol. 2023; 5:1188152.
PMID: 37637478 PMC: 10448520. DOI: 10.3389/ftox.2023.1188152.
Sprogyte L, Park M, Di Girolamo N Cells. 2023; 12(9).
PMID: 37174694 PMC: 10177508. DOI: 10.3390/cells12091294.
Zhang J, Junigan J, Trinh R, Kavelaars A, Heijnen C, Grace P J Neurosci. 2022; 42(42):7862-7874.
PMID: 36096670 PMC: 9617617. DOI: 10.1523/JNEUROSCI.1182-22.2022.
Neuropathic ocular surface pain: Emerging drug targets and therapeutic implications.
Patel S, Mittal R, Sarantopoulos K, Galor A Expert Opin Ther Targets. 2022; 26(8):681-695.
PMID: 36069761 PMC: 9613591. DOI: 10.1080/14728222.2022.2122438.